| Vehling-Kaiser, Ursula |
CAPTOR-BC, NCT05452213: Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients |
|
|
| Recruiting | 4 | 1000 | Europe | Ribociclib | Institut fuer Frauengesundheit, AGO Breast Study Group e.V., Novartis Pharmaceuticals | Breast Cancer, Breast Neoplasms, Breast Neoplasm Female, Breast Cancer Female, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Advanced Breast Cancer | 10/24 | 10/26 | | |
PREPARE, NCT03013946 / 2016-000399-28: Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy |
|
|
| Recruiting | 3 | 430 | Europe | Concomitant coaching | AIO-Studien-gGmbH, Pfizer, Crolll Gmbh | Renal Cell Carcinoma, Metastatic, Renal Cell Cancer, Recurrent | 01/24 | 07/24 | | |
CLL17, NCT04608318 / 2019-003854-99: Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL) |
|
|
| Active, not recruiting | 3 | 897 | Europe, RoW | Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro | German CLL Study Group, Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research (SAKK), Cancer Trials Ireland, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), Grupo Español de Leucemia Linfocítica Crónica (GELLC), The Israeli CLL Study Group (ICLLSG), Janssen Pharmaceutica N.V., Belgium, AbbVie, Hoffmann-La Roche | Chronic Lymphoid Leukemia | 09/27 | 09/27 | | |
LUCAS, NCT05178342: Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948 |
|
|
| Terminated | 2 | 38 | Europe | CA-4948, Emavusertib | University of Leipzig, Curis, Inc. | Myelodysplastic Syndromes, Anemia | 07/24 | 07/24 | | |
NCT04263480: Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia |
|
|
| Recruiting | 2 | 99 | Europe | Carfilzomib + Ibrutinib, Ibrutinib | Christian Buske, Amgen, Janssen, LP | Waldenstrom Macroglobulinemia | 02/28 | 02/28 | | |
| Completed | N/A | 400 | Europe | FoundationOne®CDx and FoundationOne®Liquid | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG | Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer | 08/24 | 08/24 | | |
| Kaiser, Florian |
ANTELOPE, NCT05689671: Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma |
|
|
| Recruiting | 4 | 136 | Europe | Atezolizumab, Tecentriq, Nab paclitaxel, Abraxane, Carboplatin, Pembrolizumab, Keytruda, Cisplatin, Pemetrexed | Nikolaj Frost MD, Roche Pharma AG, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Non-Small Cell Lung Cancer Metastatic | 10/25 | 10/26 | | |
| Active, not recruiting | 2 | 36 | Europe | Copanlisib, Aliqopa, Rituximab, Truxima | Christian Buske, University of Ulm, Optimapharm, X-act Cologne Clinical Research GmbH, Zentrum für Klinische Studien Ulm, Celltrion Healthcare Co., LTD, Bayer | Marginal Zone Lymphoma | 06/24 | 12/29 | | |
NCT04511455: Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment |
|
|
| Completed | 2 | 22 | Europe | Cabozantinib | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Ipsen | Hepatocellular Carcinoma Non-resectable, Metastatic Hepatocellular Carcinoma | 12/24 | 12/24 | | |
LENNON, NCT05384691: Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions |
|
|
| Recruiting | 2 | 213 | Europe | Luspatercept Injection, LUS | University of Leipzig, Celgene Corporation | Myelodysplastic Syndromes, Anemia | 07/26 | 07/27 | | |
| Completed | N/A | 400 | Europe | FoundationOne®CDx and FoundationOne®Liquid | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG | Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer | 08/24 | 08/24 | | |
